Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

PURPOSE: Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both. The goal of this randomized phase II study was to evaluate two differe...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Clarke, Jennifer L., Iwamoto, Fabio M., Sul, Joohee, Panageas, Katherine, Lassman, Andrew B., DeAngelis, Lisa M., Hormigo, Adília, Nolan, Craig P., Gavrilovic, Igor, Karimi, Sasan, Abrey, Lauren E.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2009
Teme:
Original Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2727290/
https://ncbi.nlm.nih.gov/pubmed/19506159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.7944
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki